Matthew Crabtree, DO
Endocrinology, Diabetes & Metabolism · Myrtle Beach, SCNPI 1861951675
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $900, more than ten times the $14 reported in 2022. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in SC, where the typical reported total is $2,665.
Across 88 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$326
- UCB, Inc.$310
- Novo Nordisk$259
- Radius Health, Inc.$99
- Xeris Pharmaceuticals, Inc.$94
- Dexcom, Inc.$77
- plus $543 from 16 others
What the payments were for
- Food & beverage$1,67698%
- Education$322%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 18 | $326 |
| UCB, Inc. | 15 | $310 |
| Novo Nordisk | 11 | $259 |
| Radius Health, Inc. | 5 | $99 |
| Xeris Pharmaceuticals, Inc. | 6 | $94 |
| Dexcom, Inc. | 5 | $77 |
| BETA Bionics, Inc. | 2 | $59 |
| Novartis | 4 | $56 |
| Ascendis Pharma Endocrinology Inc | 2 | $49 |
| AbbVie | 3 | $49 |
| Sanofi-aventis U.S. LLC | 2 | $47 |
| Boehringer Ingelheim | 2 | $46 |
| Lilly USA, LLC | 3 | $43 |
| Ascensia Diabetes Care US Inc. | 2 | $40 |
| Ardelyx, Inc. | 1 | $30 |
| Calliditas Therapeutics US Inc. | 1 | $22 |
| Madrigal Pharmaceuticals | 1 | $22 |
| Bayer | 1 | $18 |
| Fresenius Kabi USA, LLC | 1 | $17 |
| Scilex Pharmaceuticals Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $16 |
| GRT US Holding, Inc. | 1 | $14 |
How this compares
$1,708 in reported general payments places this provider in the 45th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
See all endocrinology, diabetes & metabolism providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 93 | $143,026 |
| JardianceEmpagliflozin | 74 | $108,916 |
| TrulicityDulaglutide | 44 | $82,900 |
| MounjaroTirzepatide | 36 | $54,454 |
| Tresiba Flextouch U-200Insulin Degludec | 39 | $51,076 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $26,430 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 15 | $24,264 |
| Novolog FlexpenInsulin Aspart | 59 | $18,788 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $16,039 |
| Humalog Kwikpen U-100Insulin Lispro | 47 | $16,002 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 71 | $10,943 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 17 | $8,712 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $7,810 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $7,067 |
| HumalogInsulin Lispro | 18 | $6,543 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $43 | $143,89798 claims |
| Novo NordiskOzempic | $259 | $143,02693 claims |
| Boehringer IngelheimJardiance | $46 | $108,91674 claims |
| AbbVieSynthroid | $49 | $2,46825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
Other endocrinology, diabetes & metabolism in Myrtle Beach
- Gauri DhirMyrtle Beach$417K
- Donald EagertonMyrtle Beach$284K
- Anne LarochelleMyrtle Beach$32K
- Jocelyn MyersMyrtle Beach$26K
- Alimitha KodaliMyrtle Beach$5K
- Zhiwei ZhangMyrtle Beach$3K
- Paul BunnMyrtle Beach$3K
- Sahana ParthasarathyMyrtle Beach$2K
- Cory WhiteGreenville$413K
- Louis HaenelCharleston$377K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.